Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffery Testani

Cardiovascular Disease New Haven, CT Medical Doctor

NPI 1588729750 CMS profile 550586

333 Cedar St., New Haven, CT 06520

Open in the dashboard

General payments

$545,812

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,843,586 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffery Testani of New Haven, CT is reported in the CMS Open Payments database as having received $545,812 across 132 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,843,586 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89,684 24
2024 General $44,488 6
2023 General $41,951 19
2022 General $48,176 21
2021 General $43,425 16
2020 General $29,635 9
2019 General $248,454 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffery Testani
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jeffery Testani were reported at $89,684. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jeffery Testani Cardiovascular Disease median Middle half National median
2019 $248,454 $450 $127–$1,392 $163
2020 $29,635 $242 $77–$751 $114
2021 $43,425 $335 $101–$1,037 $132
2022 $48,176 $395 $121–$1,211 $149
2023 $41,951 $443 $136–$1,283 $160
2024 $44,488 $450 $136–$1,323 $164
2025 $89,684 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi US Services Inc. $184,275 5 payments
  2. Eli Lilly and Company $100,317 24 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $68,254 16 payments
  4. Boehringer Ingelheim International GmbH $46,085 22 payments
  5. E.R. Squibb & Sons, L.L.C. $40,410 5 payments
  6. Merck Sharp & Dohme Corporation $24,794 10 payments
  7. AstraZeneca Pharmaceuticals LP $23,326 14 payments
  8. Bard Peripheral Vascular, Inc. $22,913 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $12,938 7 payments
  10. Terumo Medical Corporation $7,875 2 payments
  11. Other $14,627 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $319,951 64 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $182,597 5 payments
  3. Travel and Lodging $41,917 36 payments
  4. Food and Beverage $1,347 27 payments
Products named General payments · program years 2019–2025
  1. SOTAGLIFLOZIN $184,275 5 payments
  2. Non-Covered $39,855 11 payments
  3. JARDIANCE Diabetes $20,206 11 payments
  4. Non-Covered $7,475 4 payments
  5. FARXIGA $5,543 9 payments
  6. Veltassa $2,500 1 payment
  7. JARDIANCE Diabetes $1,858 1 payment
  8. Product in Development $875 1 payment
  9. OPTIMIZER Cardiovascular Device $80 1 payment
  10. OPTIMIZER Cardiovascular Device $80 1 payment
  11. Other $60 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$5,126

Medicare's payments for the services billed

Medicare patients

46

Average age 74

Services billed

87

25 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 70%
Arthritis 67%
Diabetes 61%
Ischemic heart disease 59%
Atrial fibrillation 57%
Chronic kidney disease 54%
Depression 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim International GmbH $1,858
$1,858 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record